Burning Rock Biotech (BNR) Capital Leases (2019 - 2020)

Burning Rock Biotech (BNR) posted quarterly Capital Leases of $116000.0 for Q3 2020, down 62.21% on a QoQ basis from $307000.0 in Q2 2020.

Burning Rock Biotech (BNR) Capital Leases (2019 - 2020) Analysis & Trends

Burning Rock Biotech (BNR) has reported Capital Leases for 2 consecutive years, with $116000.0 the latest figure, recorded in Q3 2020.

In Q3 2020, Capital Leases changed N/A year-over-year to $116000.0; the TTM figure through Sep 2020 stood at $116000.0 (changed N/A YoY), while the FY2019 annual figure was $697491.0, changed N/A from the prior year.
Capital Leases came in at $116000.0 for Q3 2020 at Burning Rock Biotech, down from $307000.0 in the prior quarter.
The five-year high for Capital Leases was $683297.8 in Q4 2019, with the low at $116000.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Waters	31,055.11 Bn	31,054.65 Bn	1.11 Bn
2	Thermo Fisher Scientific	191.02 Bn	187.77 Bn	7.74 Bn
3	Danaher	137.16 Bn	131.47 Bn	3.59 Bn
4	Idexx Laboratories	42.82 Bn	42.62 Bn	722.74 Mn
5	Natera	39.09 Bn	37.99 Bn	696.04 Mn
6	Agilent Technologies	37.61 Bn	35.81 Bn	990.00 Mn
7	Iqvia Holdings	34.23 Bn	32.25 Bn	1.36 Bn
8	Illumina	28.14 Bn	26.98 Bn	721.00 Mn
9	Mettler Toledo International	26.40 Bn	26.33 Bn	555.82 Mn
10	Burning Rock Biotech	748.66 Mn	683.48 Mn	11.31 Mn

Download Data